Literature DB >> 12063953

The assessment of biliary CA 125, CA 19-9 and CEA in diagnosing cholangiocarcinoma--the influence of sampling time and hepatolithiasis.

Chiung-Yu Chen1, Shu-Chu Shiesh, Hui-Chen Tsao, Xi-Zhang Lin.   

Abstract

BACKGROUND/AIMS: This study was conducted to assess the clinical value of biliary CA 19-9, CA 125 and CEA sampled in different situations for the diagnosis of cholangiocarcinoma.
METHODOLOGY: Bile was obtained from patients with bile duct obstruction on the day of biliary drainage and 3 days later separately. The etiology of biliary obstruction included choledocholithiasis (N = 51), hepatolithiasis (N = 19) and cholangiocarcinoma (N = 28). Patients of the former two conditions were all complicated with cholangitis.
RESULTS: The sensitivity of biliary CEA, CA 19-9 and CA 125, whenever checked were all less than 70%. The biliary CEA and CA 19-9 were elevated in the presence of cholangitis. In addition, the biliary CEA was also increased in the patients with hepatolithiasis. The specificity of CA 125 was better than those of CEA and CA 19-9 (75.7% vs. 33.3% and 60%, respectively) on the day of biliary drainage. The diagnostic efficiency was slightly improved when combining biliary CA 125 and CEA.
CONCLUSIONS: As the biliary CA 125 was less affected by inflammation and hepatolithiasis, it is more useful than CEA and CA 19-9 in the diagnosis of cholangiocarcinoma. The single tumor marker test of CA 125 or combined tumor marker test of CEA and CA 125 may be used as a useful complement to other investigative methods to differentiate benign from malignant causes of the bile duct obstruction.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12063953

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  26 in total

1.  Monoclonal immunoscintigraphy for detection of metastasis and recurrence of colorectal cancer.

Authors:  Vera Artiko; Ana Koljevic Marković; Dragana Sobić-Šaranović; Milorad Petrović; Andrija Antić; Mirjana Stojković; Marinko Zuvela; Djordjije Saranović; Milica Stojković; Nebojša Radovanović; Danijel Galun; Aleksandar Milovanović; Jovica Milovanović; Anica Bobić-Radovanović; Zoran Krivokapic; Vladimir Obradović
Journal:  World J Gastroenterol       Date:  2011-05-21       Impact factor: 5.742

2.  Utility of serum CA19-9 in diagnosis of cholangiocarcinoma: in comparison with CEA.

Authors:  Xing-Lei Qin; Zhuo-Ren Wang; Jing-Sen Shi; Min Lu; Lin Wang; Quan-Ru He
Journal:  World J Gastroenterol       Date:  2004-02-01       Impact factor: 5.742

3.  Detection of early-stage extrahepatic cholangiocarcinoma in patients with biliary strictures by soluble B7-H4 in the bile.

Authors:  Wenbo Ke; Li Zeng; Yunbi Hu; Sisi Chen; Min Tian; Qinggang Hu
Journal:  Am J Cancer Res       Date:  2018-04-01       Impact factor: 6.166

Review 4.  Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment.

Authors:  Boris Blechacz; Gregory J Gores
Journal:  Hepatology       Date:  2008-07       Impact factor: 17.425

5.  Two cases of miliary tuberculosis and elevated levels of cancer antigen 125.

Authors:  M Alimagham; S Aminiafshar; Smm Hosseini Moghaddam; S Shokuhi
Journal:  Can J Infect Dis Med Microbiol       Date:  2006-03       Impact factor: 2.471

Review 6.  Advances in diagnosis, treatment and palliation of cholangiocarcinoma: 1990-2009.

Authors:  Murad Aljiffry; Mark J Walsh; Michele Molinari
Journal:  World J Gastroenterol       Date:  2009-09-14       Impact factor: 5.742

7.  Intrahepatic cholangiocarcinoma.

Authors:  Kimberly M Brown; Abhishek D Parmar; David A Geller
Journal:  Surg Oncol Clin N Am       Date:  2014-04       Impact factor: 3.495

Review 8.  Biomarkers in bile-complementing advanced endoscopic imaging in the diagnosis of indeterminate biliary strictures.

Authors:  Vennisvasanth Lourdusamy; Benjamin Tharian; Udayakumar Navaneethan
Journal:  World J Gastrointest Endosc       Date:  2015-04-16

9.  Preoperative diagnosis of lymph node metastasis in biliary and pancreatic carcinomas: evaluation of the combination of multi-detector CT and serum CA19-9 level.

Authors:  Atsushi Nanashima; Ichiro Sakamoto; Tomayoshi Hayashi; Syuuichi Tobinaga; Masato Araki; Masaki Kunizaki; Takashi Nonaka; Hiroaki Takeshita; Shigekazu Hidaka; Terumitsu Sawai; Toru Yasutake; Takeshi Nagayasu
Journal:  Dig Dis Sci       Date:  2010-03-18       Impact factor: 3.199

10.  Cholangiocarcinoma: expanding the spectrum of risk factors.

Authors:  Diaa H Elfaki; Andrea A Gossard; Keith D Lindor
Journal:  J Gastrointest Cancer       Date:  2009-01-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.